Longevity clinical trials

Explore recruiting longevity clinical trials.

Recruiting longevity studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Longevity trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER

Belgium, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement.

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A 4-way randomized double-blinded migration (RSA), bone density (DXA), and biomarker study assessing adaptive bone changes and implant fixation and longevity of the new Regenerex Porous Titanium Tibial Tray with different adjuvant medical therapies.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

(BIPAS) A prospective trial to assess Pneumococcal vaccine B cell response in patients without a spleen: a controlled study.

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors CLEER Trial (Chemotherapy Longevity by Evading EGFR Inhibitor Reactions)

Spain, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Longevity trials by city

Longevity in Toronto Longevity in Vancouver Longevity in Montreal Longevity in Calgary Longevity in Edmonton Longevity in Ottawa Longevity in Winnipeg Longevity in Quebec City Longevity in Hamilton Longevity in Kitchener Longevity in London Longevity in Halifax Longevity in New York Longevity in Los Angeles Longevity in Chicago Longevity in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease